TSE:MDNA Medicenna Therapeutics (MDNA) Stock Price, News & Analysis C$0.22 +0.04 (+22.22%) As of 03:32 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesNews and Trends About Medicenna Therapeutics Stock (TSE:MDNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medicenna Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.18▼C$0.2250-Day RangeC$0.18▼C$0.4852-Week RangeC$0.17▼C$1.78Volume462,991 shsAverage Volume87,587 shsMarket CapitalizationC$20.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company's most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe. Medicenna is also advancing MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study. The Company is also developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors using its proprietary BiSKIT and T-MASK platforms. Read More Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDNA Stock News HeadlinesMedicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp ...November 16 at 8:28 AM | theglobeandmail.comMedicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved TherapiesNovember 9, 2026 | finance.yahoo.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 19 at 1:00 AM | Behind the Markets (Ad)Medicenna Therapeutics Corp MDNANovember 5, 2026 | morningstar.comMMedicenna Therapeutics Says Enrollment for Phase 1/2 Study for It MDNA11 Drug CompleteNovember 4, 2026 | finance.yahoo.comMedicenna Says MDNA2091 Preclinical Data Shows Improved Disease Symptoms in Mouse ModelsOctober 26, 2026 | marketscreener.comMMedicenna’s MDNA209 Shows Strong CD122 Blockade and Survival Gains in Autoimmune Preclinical ModelsOctober 26, 2026 | tipranks.comMedicenna to Showcase CD122 Superantagonist MDNA209 Data at Paris Immunotherapy MeetingOctober 22, 2026 | tipranks.comSee More Headlines MDNA Stock Analysis - Frequently Asked Questions How have MDNA shares performed this year? Medicenna Therapeutics' stock was trading at C$0.92 at the beginning of the year. Since then, MDNA stock has decreased by 77.7% and is now trading at C$0.21. How were Medicenna Therapeutics' earnings last quarter? Medicenna Therapeutics Corp. (TSE:MDNA) issued its quarterly earnings results on Monday, November, 16th. The company reported C($0.04) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative trailing twelve-month return on equity of 861.02% and a negative net margin of 533,640.00%. How do I buy shares of Medicenna Therapeutics? Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medicenna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include Manulife Financial (MFC), Lightspeed Commerce (LSPD), SoFi Technologies (SOFI), NervGen Pharma (NGENF), Antibe Therapeutics (ATE), Canadian Natural Resources (CNQ) and Freehold Royalties (FRU). Company Calendar Last Earnings11/16/2026Today11/19/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolTSE:MDNA CIKN/A Webwww.medicenna.com Phone+1-403-6807898FaxN/AEmployees15Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$25.98 million Net Margins-533,640.00% Pretax MarginN/A Return on Equity-861.02% Return on Assets-32.80% Debt Debt-to-Equity Ratio-4.08 Current Ratio0.69 Quick Ratio4.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.18 per share Price / Cash Flow1.15 Book ValueC($0.02) per share Price / Book-8.87Miscellaneous Outstanding Shares92,300,000Free FloatN/AMarket CapC$18.92 million OptionableNot Optionable Beta2.49 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (TSE:MDNA) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.